Skip to main content

TD Cowen Sticks to Its Buy Rating for AbCellera Biologics (ABCL)

Tipranks - Tipranks - Fri Sep 12, 2025

In a report released today, Brendan Smith from TD Cowen maintained a Buy rating on AbCellera Biologics. The company’s shares closed yesterday at $4.28.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Smith covers the Healthcare sector, focusing on stocks such as Codexis, OmniAb, and Cytek Biosciences. According to TipRanks, Smith has an average return of 0.8% and a 42.98% success rate on recommended stocks.

AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $9.20.

See Insiders’ Hot Stocks on TipRanks >>

Based on AbCellera Biologics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $17.08 million and a GAAP net loss of $34.73 million. In comparison, last year the company earned a revenue of $7.32 million and had a GAAP net loss of $36.93 million

Read More on ABCL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).